Valtrex (valaciclovir), the aciclovir prodrug licensed for genital herpes, herpes labialis, herpes zoster and, in the UK/EU, post-transplant CMV prophylaxis, is available from M Care as the originator brand or a long-genericised valaciclovir tablet, quoted against your tender specification.
Valtrex (valaciclovir), originated by GlaxoSmithKline, is an oral prodrug that converts almost completely to aciclovir after absorption, giving three to five times higher bioavailability than oral aciclovir itself at a lower daily tablet count. M Care Exports is a merchant exporter: we source Valtrex and FDA- and MHRA-approved generic valaciclovir tablets through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Valaciclovir exporter and bulk supplier from India.
For hospital pharmacy, wholesaler and MoH tender orders, M Care quotes valaciclovir tablets against buyer specification: brand (Valtrex) or generic, strength mix (250 mg, 500 mg, 1000 mg) and destination-market regulatory documentation, drawn from licensed WHO-GMP manufacturer lines on the M Care roster. Because dosing and duration differ sharply by indication, cold sores, genital herpes, shingles, chickenpox or transplant CMV prophylaxis, we confirm the buyer's intended indication mix and any renal-impairment dosing protocol before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Nucleoside analogue antiviral; aciclovir prodrug, sourced and documented for export.
Valaciclovir is the L-valyl ester prodrug of aciclovir, a nucleoside analogue that, once phosphorylated by viral thymidine kinase inside an infected cell, inhibits herpes DNA polymerase and halts viral replication. After oral dosing it is rapidly and almost completely converted to aciclovir by intestinal and hepatic enzymes, which is why it is dosed as a tablet rather than injected, and why fewer daily doses achieve aciclovir exposure that oral aciclovir itself cannot match. US labelling covers herpes labialis (cold sores), genital herpes (initial and recurrent episodes, chronic suppressive therapy, and reduction of transmission risk to a seronegative partner) and herpes zoster (shingles) in adults, plus chickenpox and cold sores in defined paediatric age bands. UK/EU labelling additionally covers ophthalmic zoster and, at a high dose, prophylaxis of cytomegalovirus disease after solid organ transplantation. Valaciclovir is supplied as 250 mg, 500 mg and 1000 mg film-coated tablets, taken orally with no reconstitution step.
Active ingredient
Valaciclovir hydrochloride (converted in vivo to aciclovir). Nucleoside analogue antiviral; aciclovir prodrug.
Forms and strengths
250 mg film-coated tablet; 500 mg film-coated tablet; 1000 mg film-coated tablet.
Indications
Valaciclovir is the L-valyl ester prodrug of aciclovir, rapidly converted after oral absorption to give higher bioavailability than aciclovir itself. Indicated for genital herpes, herpes labialis, herpes zoster and, in UK/EU labelling, post-transplant CMV prophylaxis. Supplied as originator Valtrex and long-genericised generic tablets from Indian channels to regulated and semi-regulated markets outside India.
Administration
Oral. Film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for valaciclovir are hospital dermatology, genitourinary medicine and transplant-unit pharmacies managing herpes and post-transplant CMV protocols, paediatric wards using the chickenpox regimen, national and regional MoH tender desks running antiviral formulary lists, licensed pharmaceutical wholesalers and importers, and retail pharmacy chains across our GCC and African markets stocking a prescription antiherpes line where local scheduling permits.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on valaciclovir.
Dosing is indication-led, not one regimen: cold sores take 2 g twice in a single day twelve hours apart; recurrent genital herpes is 500 mg twice daily for three days while an initial episode runs 1 g twice daily for up to ten days; suppressive therapy drops to 500 mg once daily in immunocompetent adults; shingles is 1 g three times daily for seven days, extended in immunocompromised patients until lesions crust; and UK/EU-licensed CMV prophylaxis after transplant is a much higher 2 g four times daily for around ninety days. Aciclovir, the active metabolite, is cleared renally, so every regimen needs dose or interval adjustment once creatinine clearance falls below 50 mL/min, applying the manufacturer's renal-adjustment table at dispensing rather than a flat reduction. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, in some cases fatal, have been reported in patients with advanced HIV-1 disease and in transplant recipients on high-dose regimens, so any unexplained bruising, confusion or falling platelet count during high-dose therapy warrants immediate discontinuation. Severe cutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, mean valaciclovir or aciclovir must never be restarted after such a reaction. No cold-chain handling is required; tablets store at controlled room temperature.
The documentation pack a regulator actually asks for.
As an oral film-coated tablet, valaciclovir ships on standard ambient-temperature logistics rather than the validated cold-chain lanes M Care runs for biologics and injectables. What buyers need instead is batch-level certificate of analysis, CDSCO export documentation and, where the destination market requires it, CTD or eCTD-format dossier support so the buyer's own regulator can register the product; UK shelf life is three years, stored below 30 degrees C. Aciclovir itself has sat on the WHO Model List of Essential Medicines since 1997 (most recently reaffirmed 2025, TRS 1064) in oral, ophthalmic and intravenous forms for herpes simplex, varicella and zoster; valaciclovir is not itself a separate WHO-EML entry, so oral aciclovir remains the EML reference agent and tender desks should treat valaciclovir as a formulary upgrade for adherence and bioavailability rather than an EML-listed molecule in its own right. On the brand-versus-generic question, this patent expired years ago: FDA-approved generic valacyclovir tablets from multiple ANDA holders and MHRA-licensed generic valaciclovir tablets are both separately registered and marketed alongside GlaxoSmithKline's originator Valtrex in the US, UK and EU, so buyers genuinely have a brand-or-generic choice on a standard bioequivalence basis. Valaciclovir is not a scheduled controlled substance in the markets M Care serves. M Care does not manufacture valaciclovir itself and holds no WHO-GMP or WHO-PQ certification in its own name; every batch exported carries its manufacturing partner's own certification.
How a licensed importer actually brings a consignment like this in is covered once, in the licensed import route guide, rather than repeated on every molecule page.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside valaciclovir.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for valaciclovir.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Valaciclovir supply, the specific questions.
Does a generic version of Valtrex exist?
Yes. FDA-approved generic valacyclovir tablets from multiple ANDA holders and MHRA-licensed generic valaciclovir tablets are both separately registered and marketed in the US, UK and EU alongside GlaxoSmithKline's originator brand Valtrex. Registration status varies by destination country, so M Care checks local approval before quoting brand or generic against a specific tender.
What is valaciclovir licensed to treat?
US labelling covers herpes labialis (cold sores), genital herpes (initial and recurrent episodes, chronic suppression, and reduction of transmission risk to a seronegative partner) and herpes zoster in adults, plus chickenpox and cold sores in defined paediatric age groups. UK/EU labelling additionally covers ophthalmic zoster and, at a higher dose, cytomegalovirus prophylaxis after solid organ transplantation. Check destination-country labelling before a tender submission.
What strengths of valaciclovir tablets does M Care supply?
250 mg, 500 mg and 1000 mg film-coated tablets, matching the strengths registered under Valtrex and licensed generic lines. Tell us your indication mix, cold sores, genital herpes, shingles, chickenpox or transplant CMV prophylaxis, and we quote the strength split accordingly.
Is valaciclovir on the WHO Essential Medicines List?
Not as a separate entry. Aciclovir, the active metabolite valaciclovir converts to in the body, has been on the WHO Model List of Essential Medicines since 1997 and was reaffirmed in 2025. Valaciclovir is not itself WHO-EML-listed, so tender desks should treat it as a higher-bioavailability formulary upgrade over oral aciclovir rather than an EML first-line agent in its own name.
Does valaciclovir need special safety monitoring?
At high doses, thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, in some cases fatal, have been reported in patients with advanced HIV-1 disease and in transplant recipients, so unexplained bruising, confusion or a falling platelet count on high-dose therapy warrants immediate discontinuation. Severe cutaneous reactions such as Stevens-Johnson syndrome mean the drug must never be restarted after such a reaction. Renal dosing adjustment is also required once creatinine clearance falls below 50 mL/min.
What documentation does M Care provide with a valaciclovir shipment?
Batch-level certificate of analysis, CDSCO export documentation from the Indian side, and CTD/eCTD-aligned dossier support where the destination regulator requires local registration before import, alongside confirmation of exactly which brand or generic product a shipment contains.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-19.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.